Brief: Cytokinetics Plans To Submit Supplemental NDA To U.S. FDA For Aficamten In Q4 2026
28/08/2026 10:45
BRIEF-Cytokinetics Plans To Submit Supplemental NDA To U.S. FDA For Aficamten In Q4 2026 Aug 28 (Reuters) - Cytokinetics, Incorporated CYTK.O:
CYTOKINETICS: PLANS TO SUBMIT SUPPLEMENTAL NDA TO U.S. FDA FOR AFICAMTEN FOR TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC NHCM IN Q4
Further company coverage: CYTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytokinetics, Incorporated
See all newsBrief: Cytokinetics To Announce Third Quarter Results On November 4, 2026
Brief: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Cytokinetics Announces Additional Data From Acacia-Hcm Presented At The Hfsa Annual Scientific Meeting 2026
Brief: Cytokinetics Launches Aspen-Hcm A Real-World Study Evaluating Myqorzo® (Aficamten) In Symptomatic Obstructive Hypertrophic Cardiomyopathy
U.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech